このエントリーをはてなブックマークに追加
ID 31618
JaLCDOI
フルテキストURL
著者
Nishiya, Koji Kochi Medical School
Hisakawa, Naoko Kochi Medical School
Tahara, Kiyoshi Kochi Medical School
Matsumori, Akinori Kochi Medical School
Ito, Hiroyuki Kochi Medical School
Hashimoto, Kozo Kochi Medical School
Nakatani, Ko Misato Marine Hospital
Takatori, Kazuhiro Okayama Saidaiji Hospital
抄録

To evaluate the efficacy and safety of additive triple disease modifying anti-rheumatic drug (DMARD) combination therapy of a low dose of sulfhydryl compounds inverted question markD-penicillamine, bucillamine or tiopronin inverted question mark, sulfasalazine (SSZ) and methotrexate (MTX) as a treatment for rheumatoid arthritis (RA) patients, we studied a total of 33 Japanese RA patients (6 males, 27 females). At 1 or 2 months after simultaneous administration of the 3 above-mentioned DMARDs was begun, significant improvements were seen in markers of joint inflammation, i.e., erythrocyte sedimentation rate and C-reactive protein in sera. At 6 months, clinical improvement judged by the physicians' overall assessment of joint symptoms and laboratory data was observed in 29 (88%) of the 33 RA patients. No marked effect was observed in the other 4 (12%) patients, however. We observed no significant adverse reaction to this therapy. This suggests that additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, SSZ and MTX could be a useful drug therapy for the treatment of RA patients, even those who are refractory.

キーワード
rheumatoid arthritis
joint inflammation
disease modifying anti-rheumatic drug
combination therapy
Amo Type
Brief Note
発行日
1999-12
出版物タイトル
Acta Medica Okayama
53巻
6号
出版者
Okayama University Medical School
開始ページ
275
終了ページ
279
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT